2. Disease Areas
  3. Infection
  4. Bacterial Infection
  5. Haemophilus Influenza Infection

Haemophilus Influenza Infection

Haemophilus influenzae is a Gram-negative, facultative anaerobic, nonmotile, non-spore-forming bacterium that is part of the normal nasopharyngeal flora and can cause invasive infections, especially in immunocompromised hosts or young children. It is characterized by a polysaccharide capsule, which contributes to its virulence and is the basis for serotyping (with type b being most commonly associated with severe disease). The organism requires specific growth factors—X factor (protoporphyrin IX) and V factor (NAD or NADP)—for optimal aerobic growth, which are typically provided by blood components; this dependency led to its name "Haemophilus" (blood-loving). It exhibits pleomorphism in morphology, appearing as coccobacilli or filamentous forms on stained smears, and may be misidentified due to inconsistent staining. Satellitism around Staphylococcus aureus colonies on agar plates is a useful diagnostic feature due to the release of V factor. Although it grows best in 5–10% CO₂, it can survive under ambient conditions. Despite early misconceptions linking it to influenza, H. influenzae is now recognized as a major cause of respiratory tract infections, meningitis, epiglottitis, septic arthritis, and other invasive diseases, particularly in unvaccinated populations.

Haemophilus Influenza Infection (5):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-111127
    LY164846 92218-37-6
    LY164846 is an orally active cephalosporin. LY164846 is highly sensitive to Haemophilus influenzae (including Ampicillin (HY-B0522)-resistant strains) and Moraxella catarrhalis (with MIC90 ≤ 4 μg/mL). LY164846 is generally sensitive to Methicillin (HY-121544)-resistant Staphylococcus aureus and Streptococcus (except Enterococcus) (with MIC90: 0.25 - 8 μg/mL), and moderately sensitive to anaerobic bacteria. LY164846 has MBC/MIC ratio to Haemophilus influenzae of ≤ 2, showing bactericidal activity. LY164846 can be used for research on respiratory and skin infections.
    LY164846
  • HY-W653770
    Desmycosin 11032-98-7
    Desmycosin is a macrolide antibiotic. Desmycosin exhibits biological activity against H. influenzae, S.aureus, S. pneumoniae, and S. pyogenes with MIC values of 4, 1, <0.125, and <0.125 µg/ml, respectively. Desmycosin is an acidic degradation product of tylosin.
    Desmycosin
  • HY-W744633
    Cefdaloxime 80195-36-4
    Cefdaloxime is an orally active cephalosporin and HR-916 ester metabolite. Cefdaloxime has a broad spectrum of activity against pathogens such as the majority of members of the family Enterobacteriaceae, staphylococci, Streptococcus spp., Neisseria gonorrhoeae, Moraxella catarrhalis, Haemophilus influenzae.
    Cefdaloxime
  • HY-111034
    CGP 31523A 94714-78-0
    CGP 31523A is a broad-spectrum aminothiazole cephalosporin. CGP 31523A exhibits potent inhibitory effects on Enterobacteriaceae, Neisseria, Haemophilus influenzae, and Streptococcus (except Enterococcus faecalis), among others. CGP 31523A can be hydrolyzed by the common Escherichia coli type Ic β-lactamase, but is stable against the Ia type enzyme. CGP 31523A is neither an effective β-lactamase inhibitor nor does it induce the production of β-lactamase. CGP 31523A can be used for studying infections caused by Gram-negative bacteria (including drug-resistant strains).
    CGP 31523A
  • HY-105560
    Cefcanel 41952-52-7
    Cefcanel is an orally active cephalosporin and antibacterial agent. Cefcanel inhibits growth of methicillin-susceptible Staphylococcus aureus, methicillin-susceptible Staphylococcus epidermidis, Haemophilus influenzae, Moraxella catarrhalis. Cefcanel acts as a substrate hydrolyzed by TEM-1, TEM-3, and Moraxella Bro-1 beta-lactamases.
    Cefcanel